API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
U.S FDA has given Abbreviated New Drug Application labetalol hydrochloride injection USP, 100 mg/20 mL (5 mg/mL) and 200mg/40 mL (5 mg/mL) multiple-dose vials, a generic therapeutic equivalent version of Trandate injection, of Sebela Ireland Limited.
Lead Product(s): Labetalol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
The five medicines include: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9% sodium chloride injection. Deal aims support to healthcare providers, helping to meet the immediate and long-term supply needs of drugs necessary to a range of patient care interventions.
Lead Product(s): Labetalol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ProvideGx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 21, 2021